Nkarta isolates immune cells called natural killer cells from healthy donors and engineers them for therapeutic purposes, but relies on global suppliers for key materials.
"Natural killer cells have evolved to seek and destroy abnormal cells," says Nadir Mahmood, president of Nkarta, a biotechnology company in South San Francisco, California. "And if that's deep enough to drive an immune-system reset, then you can have the reconstitution of a healthy and naive immune system."
Understanding the interactions between RIFIN proteins and immune receptors is crucial for developing strategies to combat malaria, particularly in regions heavily affected by the disease.